 |
 |
 |
||||||
 |
 |
|||||
 |
||||||
 |
 |
 |
||||
 |
||||||
 |
||||||
 |
||||||
 |
 |
|||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
||||||
 |
 |
 |
||||
 |
||||||
 |
|
|
|
|
|
|
News
November 1, 2008,
San Diego, CA
Phage’s San Diego Manufacturing Facility Received Renewal of its California State License
The Food and Drug Branch of the Department of Public Health of the State of California granted Phage the renewal of its license to manufacture pharmaceuticals for clinical and commercial use until August 2010. The plant has produced all of the FGF-1 that CardioVascular BioTherapeutics, Inc. has utilized in its pre-clinical and clinical development programs.
October 28, 2008,
San Diego, CA
Phage Enters Chapter 11 Bankruptcy
Phage Biotechnology Corporation (Phage) had an involuntary petition under the United States Bankruptcy Code for Chapter 7 filed against it October 2, 2008 by a group of petitioning creditors in the US Bankruptcy Court for the Southern District of California. After change of management (Mr. Dan Montano and Mr. Grant Gordon stepped down from all their duties at Phage), the new management of Phage filed on October 27, 2008 to convert the Chapter 7 petition to reorganization under Chapter 11. The Court approved the conversion to Chapter 11 on October 28, 2008. Phage is continuing its ordinary course of business and is working through the court system process to reorganize its affairs under Chapter 11. Business is expected to continue uninterrupted at present.
November 16, 2007,
Las Vegas, NV
Phage Engages The Bruckner Group To Find A Partner to Jointly Commercialize its Portfolio of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms
Phage Biotechnology Corporation has engaged The Bruckner Group to find a partner to jointly commercialize its portfolio of recombinant biological therapies, the products of Phage’s development platforms and technologies.
November 1, 2007,
Las Vegas, NV
Phage’s New San Diego Manufacturing Facility Receives California State License
The California Food and Drug Board granted Phage a license to manufacture pharmaceuticals for clinical and commercial use. The plant has produced all of the FGF-1 that CardioVascular BioTherapeutics, Inc. has utilized in its pre-clinical and clinical development programs.
November 14, 2006,
San Diego, CA
Phage Completes Pre-clinical Efficacy Study on PEG-Syntropin™, Its Long-Acting Human Growth Hormone Product
A 2 month efficacy study in growth-hormone deficient rats indicated that Phage’s long-acting growth hormone product, PEG-Syntropin™, injected once a week, was more potent than daily injections of native growth hormone. Additional efficacy studies in this classical weight gain bioassay for human growth hormone determined the optimal dose of PEG-Syntropin™. Toxicity studies are now underway to support initial human testing of this product, anticipated to start in the second quarter of 2007.
October 2, 2006, San Diego, CA
Phage Takes Occupancy of a New Research and Development Laboratory in San Diego, California
Phage moved into a new R&D facility situated approximately 4 miles from the University of California, San Diego campus in La Jolla, CA. The R&D facility is adjacent to Phage’s manufacturing facility which was acquired earlier in the year. The close proximity of the two facilities will permit a better integration of the activities ongoing in each of these important operational areas for Phage.
April 3, 2006, San Diego, CA
Phage Takes Occupancy of New Manufacturing Plant
Phage has completed the move of its manufacturing activities to a new 7500 square foot facility in the Sorrento Valley area of San Diego. This plant has the capacity to provide Phage and its contract manufacturing clients with lots of material for all anticipated clinical trials over the next 5 year time frame.
January 17, 2006, Las Vegas, NV
New Corporate Headquarters Opens in Las Vegas, Nevada
Phage today occupied its new corporate headquarters in Las Vegas, Nevada. The company’s chief executives are based there along with corporate administration, legal and human resources. The new office is located in the Summerlin area of Las Vegas and will house additional departments of Phage as the company expands into marketing and sales activities.
Home | Contact Us |
Webmaster
©2008 Phage Biotechnology Corp. All Rights Reserved